BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 22131995)

  • 1. Biomarkers of cervical dysplasia and carcinoma.
    Hwang SJ; Shroyer KR
    J Oncol; 2012; 2012():507286. PubMed ID: 22131995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of methods for detect human Papillomavirus infection.
    Abreu AL; Souza RP; Gimenes F; Consolaro ME
    Virol J; 2012 Nov; 9():262. PubMed ID: 23131123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anal dysplasia screening: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2007; 7(4):1-43. PubMed ID: 23074504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human papillomavirus testing and molecular markers of cervical dysplasia and carcinoma.
    Dehn D; Torkko KC; Shroyer KR
    Cancer; 2007 Feb; 111(1):1-14. PubMed ID: 17219448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of p16INK4a-cytology, HPV mRNA, and HPV DNA testing to identify high grade cervical dysplasia in women with abnormal screening results.
    Reuschenbach M; Clad A; von Knebel Doeberitz C; Wentzensen N; Rahmsdorf J; Schaffrath F; Griesser H; Freudenberg N; von Knebel Doeberitz M
    Gynecol Oncol; 2010 Oct; 119(1):98-105. PubMed ID: 20619445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of effectiveness and cost-effectiveness of HPV testing in primary screening for cervical.
    Mittendorf T; Nocon M; Roll S; Mühlberger N; Sroczynski G; Siebert U; Willich SN; von der Schulenburg JM
    GMS Health Technol Assess; 2007 Sep; 3():Doc08. PubMed ID: 21289942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Importance of the Pap smear in the age of HPV testing].
    Ghisu GP
    Ther Umsch; 2021; 78(2):93-98. PubMed ID: 33615865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of anti HPV vaccination on cervical cancer incidence and HPV induced cervical lesions: consequences for clinical management.
    Brinkman JA; Caffrey AS; Muderspach LI; Roman LD; Kast WM
    Eur J Gynaecol Oncol; 2005; 26(2):129-42. PubMed ID: 15857016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cervical cancer: screening and prevention.
    Behtash N; Mehrdad N
    Asian Pac J Cancer Prev; 2006; 7(4):683-6. PubMed ID: 17250453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cervical Cancer Screening in South Florida Veteran Population, 2014 to 2020: Cytology and High-Risk Human Papillomavirus Correlation and Epidemiology.
    Syler LB; Stobaugh CL; Foulis PR; Carlton GT; DeLand LA; Borkowski AA
    Cureus; 2021 Aug; 13(8):e17247. PubMed ID: 34540473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
    Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
    Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular cytogenetic analyses of hTERC (3q26) and MYC (8q24) genes amplifications in correlation with oncogenic human papillomavirus infection in Czech patients with cervical intraepithelial neoplasia and cervical carcinomas.
    Kuglik P; Kasikova K; Smetana J; Vallova V; Lastuvkova A; Moukova L; Cvanova M; Brozova L
    Neoplasma; 2015; 62(1):130-9. PubMed ID: 25563377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HPV mRNA test in women with minor cervical lesions: experience of the University Hospital of North Norway.
    Sorbye SW; Fismen S; Gutteberg TJ; Mortensen ES
    J Virol Methods; 2010 Oct; 169(1):219-22. PubMed ID: 20638416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.
    Cuzick J; Arbyn M; Sankaranarayanan R; Tsu V; Ronco G; Mayrand MH; Dillner J; Meijer CJ
    Vaccine; 2008 Aug; 26 Suppl 10():K29-41. PubMed ID: 18847555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for cervical cancer: new alternatives and research.
    Lörincz AT
    Salud Publica Mex; 2003; 45 Suppl 3():S376-87. PubMed ID: 14746031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
    Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
    Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany.
    Sroczynski G; Schnell-Inderst P; Mühlberger N; Lang K; Aidelsburger P; Wasem J; Mittendorf T; Engel J; Hillemanns P; Petry KU; Krämer A; Siebert U
    GMS Health Technol Assess; 2010 Apr; 6():Doc05. PubMed ID: 21289878
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.